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Background: Endometrial cancer that occurs concurrently with peritoneal malignant mesothelioma (PMM) is
difficult to diagnose preoperatively.
Case presentation: A postmenopausal woman had endometrial cancer extending to the cervix, vagina and pelvic
lymph nodes, and PMM in bilateral ovaries, cul-de-sac, and multiple peritoneal sites. Adjuvant therapies included
chemotherapy and radiotherapy. Targeted, massively parallel DNA sequencing and molecular inversion probe microarray
analysis revealed a germline TP53 mutation compatible with Li-Fraumeni-like syndrome, somatic mutations of PIK3CA in
the endometrial cancer, and a somatic mutation of GNA11 and JAK3 in the PMM. Large-scale genomic amplifications and
some deletions were found in the endometrial cancer. The patient has been stable for 24 months after therapy. One of
her four children was also found to carry the germline TP53 mutation.
Conclusions: Molecular characterization of the coexistent tumors not only helps us make the definite diagnosis, but also
provides information to select targeted therapies if needed in the future. Identification of germline TP53 mutation further
urged us to monitor future development of malignancies in this patient and encourage cancer screening in her family.
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Simultaneous occurrence of primary cancers from the
breast, ovary, and colon has been reported with endo-
metrial cancer [1]. However, coexistence of mesothelioma
with endometrial cancer is rare with only three reported
cases [2-4]. The diagnosis of endometrial cancer is usually
made via endometrial curettage prior to definitive surgery
whereas the mesothelioma would not be discovered until
surgery.
In the present study, we describe a patient with ad-
vanced endometrial cancer and a concomitant peritoneal
malignant mesothelioma (PMM). Hematoxylin and eosin
stains and the immunoprofile of tumor tissues differenti-
ated the two tumors. Furthermore, we used targeted,* Correspondence: knoxtn@cgmh.org.tw
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sion probe (MIP)-based microarray analysis to molecularly
characterize these tumors. The genetic make-up of the
concomitant tumors of this patient was determined, and
identification of a germline TP53 mutation indicating
Li-Fraumeni-like syndrome in this patient encouraged fur-
ther screening for this mutation in her family members.
Case presentation
A 54-year-old female patient, gravida 5, para 4, with the
history of one elective abortion, suffered from abnormal
postmenopausal bleeding for two weeks. She was referred
from a local clinic where the diagnosis of adenocarcinoma
was made based on the results of a cervical biopsy. She
had no known asbestos exposure. Her father died of hepa-
tocellular carcinoma at 70 years of age. Pelvic examination
showed a necrotic cervical tumor that extended poster-
iorly, shortening the posterior fornix. Pathology indicated
that the cervical tumor was a poorly-differentiated adeno-
carcinoma, which was carcinoembryonic antigen (CEA)his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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terone receptor (PR) (3+). The results were compatible
with an endometrial origin. Magnetic resonance imaging
(MRI) revealed a mass invading the endometrium and
both cervical lips as well as tumor implants in the pouch
of Douglas and the supravesical pouch. Positron emission
tomography (PET) showed fluorodeoxyglucose uptake in
the cervix and uterus. Her surgical staging, using the
International Federation of Gynecology and obstetrics
(FIGO) guidelines, was IIb. Final pathologic diagnosis was
endometrioid adenocarcinoma with cervical extension,
positive vaginal margin, and bilateral pelvic lymph node
metastases, upstaging the malignancy to FIGO stage
IIIc, grade 3. Intriguingly, a co-existent mesothelioma,
T2N0M0, was discovered extended to bilateral ovaries,
peritoneum, omentum, multiple mesenteric sites, cul-de-
sac, and bladder serosa. Residual disease of mesothelioma
of less than 5 mm was noted. These mesothelioma tissues
were positive for calretinin and cytokeratin (CK)5/6, but
negative for ER, PR, and epithelial cell adhesion molecule
(EpCAM, Ber-EP4) (Figure 1). CK5/6 and calretinin are
often positive in mesothelial cells and mesothelial tumors,
but negative in adenocarcinoma. Ber-EP4, on the other
hand, is frequently positive in adenocarcinoma, but nega-
tive in mesothelial cells. Therefore, the immunostaining
results supported the diagnosis of mesothelioma.Figure 1 Hematoxylin and eosin (H&E) stains and immunohistochemi
cancer. (B) H&E stain; peritoneal malignant mesothelioma (PMM). High exp
PMM. Scale bars represent 500 μm in (A), 50 μm in (B), and 100 μm in (C &The patient received chemotherapy with cisplatin
(75 mg/m2) and premetrexed (Alimta, 500 mg/m2)
every 3 weeks for a total of 6 cycles. She also received
concurrent radiation to the pelvis (5040 cGy) with
brachytherapy (200 cGy) for cervical extension and
positive vaginal margins of the endometrial cancer.
Subsequently, small field radiation therapy was given
to the hepato-renal region (6000 cGy/25 fractions) to
treat the PMM. The patient has remained clinically
stable for 24 months though her follow-up computed
tomography did show stationary lesions at Morrison’s
pouch at the 24-month follow-up visit.
For molecular diagnosis, formalin-fixed paraffin-
embedded (FFPE) tissues of these two tumors and
blood DNA of the patient were sequenced using tar-
geted MPS (TruSeq Amplicon Cancer Panel, Illumina).
Genomic profiling of tumor tissues was done with MIP-
based microarray analysis (Oncoscan, Affymetrix). The
results are summarized in Table 1. Detailed results
from the MPS are listed in Additional file 1, while the
MIP-based microarray analyses are in Additional files 2
and 3. The TP53 mutation (Pro72Arg) found in blood
and both tumors was confirmed with Sanger sequencing.
Of note, among 4 somatic point mutations in this case,
only the PIK3CA mutation (c.1624 G > A p.E542K) was
detected by both MPS and MIP microarray.cal studies for two primary cancers. (A) H&E stain; endometrial
ression of (C) calretinin and (D) CK5/6 is shown in brown color in
D).
Table 1 Summary of mutated genes in endometrial cancer (Em Ca) and peritoneal malignant mesothelioma (PMM)
measured using massively parallel sequencing (MiSeq) and molecular inversion probe microarray (OncoScan)
Em Ca (35%)‡ PMM (70%)‡








TP53* 215G > C Pro/Arg 17 + (55%) NA + (33%) NA
PIK3CA 1624G > A Glu/Lys 3 + (34%) + - -
GNA11 973 T > C Tyr/His 19 - NA + (32%) NA
JAK3 703C > T Ser/Asn 19 - NA + (44%) NA
Abbreviation: MIP molecular inversion probe.
*This mutation is also found in patient’s blood.
‡Numbers in the brackets indicate the percentage of tumor cells observed by the pathologist.
#Numbers indicate the percentage of alternate alleles.
ξAnalyzed by “somatic mutation viewer” (Additional file 3), NA: data not available.
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1qter, 2, 7, 8, 9, 10, 12, 14q11.2-14pter, 17, 19p13.3-19p12,
and 19p13.2-19q13.42, deletions in 18q22.1-18q23,
and loss-of-heterozygosity (LOH) in 3p26.3-3p14.1 and
10q22.1-10q26.3 were detected in the endometrial can-
cer using the Nexus 6 Copy Number software algorithms
for the MIP microarray (Figure 2 and Additional file 2).
Only a small number of copy number aberrations and
LOH were present in the mesothelioma tumor cells
(amplification in 16p11.2 and LOH in 3p21.31-3p21.1).
Frequent genomic amplifications reported by The Cancer
Genome Atlas Research Network (TCGA) [5], including
LRP1B (2q21.2), MYC (8q24.12), SOX17 (8q11.23),
ERBB2 (17q12), and CCNE1 (19q12), were also found
in the endometrial cancer cells.Figure 2 Schematic representation of the genomic alterations in endom
mesothelioma (PMM, the lower panel) detected with molecular inversio
losses in red. The genomic regions with loss of heterozygosity are marked in
reported in The Cancer Genome Atlas Research dataset of endometrial cance
in chromosome 10q23-2-23.31, where a tumor suppressor gene PTEN was de
in chromosome 19q12, where cyclin E1 gene (CCNE1) was amplified in endomThe germline TP53 mutation (Pro72Arg) was compat-
ible with Li-Fraumeni-like syndrome. After genetic coun-
seling with her family members, three of her four children
agreed to genetic testing for this mutation. One of her
sons was found to carry the TP53 germline mutation
[E+ (mut/wt)], but her two daughters were negative for
the mutation (E-) (Figure 3) [6].Discussion
To our knowledge, this is the first case of endometrial can-
cer complicated by PMM where molecular characterization
has been performed. Immunohistochemical results of cal-
retinin (+), CK5/6 (+), ER (-), and PR (-) in PMM were
instrumental in differentiating between the two tumors. Aetrial cancer (Em Ca, the upper panel) and peritoneal malignant
n probe microarrays. (A) Copy number gains are shown in blue and
yellow color. Important genes with high frequency of amplification
r are also present in this case. (B) Detailed genomic alterations are shown
leted in endometrial cancer. (C) Detailed genomic alterations are shown
etrial cancer.
Figure 3 Gene testing showed the proband (arrow) and one son were heterozygous for the TP53 germline mutation [E+ (mut/wt)].
Her two daughters were homozygous for the wild-type TP53 gene (E-). ‘E’ represents test information on the pedigree. The arrow indicates the
proband. The asterisk indicates the kindred who had been examined for the TP53 gene mutation. Abbreviations: dx., diagnosis as; Emca, endometrial
cancer; PMM, peritoneal malignant mesothelioma; y, years old. The pedigree was generated according to the recommendations for Pedigree
Standardization Task Force of the National Society of Genetic Counselors.
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metastasized from the gastrointestinal tract [7].
Surgery for advanced endometrial cancer is challenging.
Optimal cytoreduction provides a survival benefit for
patients with advanced endometrial cancer [1]. However,
the accurate preoperative evaluation of the disease extent
to predict the demands of optimal debulking during pri-
mary surgery remains difficult. In this case, preoperative
imaging studies of MRI and PET did not show evidence of
lymph node metastasis. Concurrence of another second
primary malignancy further complicated treatment course.
In this case, extensive peritoneal implants were mistakenly
considered as tumor metastasis. Therefore, the findings of
peritoneal metastatic sites during operation should remind
operators of the possibility of a co-existing primary cancer.
Adjuvant therapies of patients with concurrent endometrial
cancer and PMM have not yet been standardized. Radiation
therapy has been reported to be the adjuvant therapy
of choice, and effective systemic chemotherapies have
improved response rates in endometrial cancer [1,8]. Pre-
metrexed has been used in combination with a platinum-
base chemotherapy as the treatment for PMM [7].
Because the diagnosis of multiple concurrent primary
cancers is often made based on micropathological results,
the tissues available for further molecular characterization
are in FFPE blocks. For FFPE DNA, targeted MPS [9]
and MIP microarrays [10] have proved to be useful in
analyzing genomic alterations. Targeted MPS can detect
mutations in 48 cancer related genes (Additional file 1).
Copy number variations (gains or losses) and LOH incancer genomes can be further identified using MIP
microarrays. Her endometrial cancer had somatic cancer
mutations in PIK3CA, which is frequently reported in
endometrial cancer [5]. Identification of these mutations
may have therapeutic implications. For instance, dysfunc-
tions in the PIK3CA pathways have been successfully
treated with PI3K/AKT/mTOR pathway inhibitors [11].
Though copy number variations were found only in small
genomic regions of PMM, it harbored GNA11. Mutation
of GNA11 in uveal melanoma [12] leads to the activation
of downstream mitogen-activated protein kinase (MAPK/
ERK) pathways. Clinical trials of inhibitors that disrupt
MAPK pathways are being assessed in the treatment of
metastatic uveal melanoma [12]. Given the fast pace of
current development of targeted drugs aiming at common
cancer mutated genes, the identification of multiple muta-
tions in this case may justify her enrollment in future
clinical trials of targeted therapy.
Germline TP53 mutations have been reported in 80% of
families who have classical Li-Fraumeni syndrome, and 20-
40% of families who meet the criteria for Li- Fraumeni-like
syndrome [13]. The prevalence of Li-Fraumeni syndrome
is rare, with approximately 400 families reported world-
wide [14]. However, Li-Fraumeni syndrome may be under
reported due to the strict requirement of clinical features
and detailed family histories to make the diagnosis.
The Pro72Arg variants of TP53 has been associated
with various cancer susceptibility and poor outcomes [15],
such as human papillomavirus 16-positive cervical cancer
[16], laryngeal tumors [17], head and neck cancers [18],
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Hisada et al reported an increased risk of developing
second cancer in patients with a germline TP53 mutation,
with a cumulative probability of 57% of developing a
second cancer at 30 years after diagnosis of the first cancer
[21]. Clinical management of the patient may include
tumor surveillance of other organs such as breast examin-
ation [22]. It is advisable that family members take a
systematic approach to cancer screening and participate
in TP53 research programs [22].
Conclusions
In conclusion, concurrent endometrial cancer and PMM are
difficult to be diagnosed pre-operatively. Effective treatments
for such patients are not standardized, and the prognosis is
unclear. Molecular characterization of the coexistent tumors
not only helps us make definitive diagnosis but also provides
information for choosing targeted therapies in the future. In
cases of Li-Fraumeni-like syndrome, family members should
also be enrolled in cancer screening.
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